February 1, 2003Clinical ScienceOpen Access

Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia

View Full Paper

Ask AI

Bookmark

Why the study?

Does complete androgen suppression increase arterial stiffness and alter metabolic risk factors in men with prostate cancer?

Population

31 men, comprising 16 men with prostate cancer and 15 control men.

Comparison

Complete androgen suppression with… vs Control men without androgen suppression

Design

Cohort

Follow-up

3 months

Authors

FDFrances DockerySt. Joseph Hospital CBChristopher J. BulpittPreventive Cardiology SASanjiv AgarwalUSC Norris Comprehensive Cancer Center

Discussion

Member takes

Implication

Androgen suppression was associated with arterial stiffening and metabolic worsening; hypothesis-generating for CV risk in prostate cancer, needing prospective confirmation.

Structured PICO

Does complete androgen suppression increase arterial stiffness and alter metabolic risk factors in men with prostate cancer?

Population

31 men, comprising 16 men with prostate cancer (mean age 71+/-9 years) and 15 control men (mean age 70+/-7 years).

Intervention

Complete androgen suppression with gonadotrophin-releasing hormone analogues for 3 months

Comparator

Control men without androgen suppression

Outcome

Arterial stiffness measured by systemic arterial compliance (SAC) and pulse wave velocities (PWVs) at 3 monthssurrogate

Testosterone suppression in men with prostate cancer leads to increased arterial stiffness and hyperinsulinemia, which may adversely affect cardiovascular risk.

Cite This Study

Dockery et al. (2003) studied this question.

synapsesocial.com/papers/6a6fc07df44fa9f079dd3d4c https://doi.org/10.1042/cs20020209

View Full Paper

Ask AI

Bookmark

Implication

Androgen suppression was associated with arterial stiffening and metabolic worsening; hypothesis-generating for CV risk in prostate cancer, needing prospective confirmation.